Hot
Mouse CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)Cat. No. CD7-M5252
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| CD27 | HOT CD7-M5252 | Mouse CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $395.00 100ug | |
| CD27 | HOTAvitag TN7-H82F6 | Biotinylated Human CD27 / TNFRSF7 Protein, Fc,Avitag™ | Human | HEK293 | ![]() | SDS-PAGE | $360.00 25ug | |
| CD27 | HOT CD7-H522b | Human CD27 / TNFRSF7 Protein, His Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $395.00 100ug | |
| CD27 | HOT CD7-H5257 | Human CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug | |
| CD27 | HOT CD7-C5259 | Cynomolgus / Rhesus macaque CD27 / TNFRSF7 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified) | Cynomolgus / Rhesus macaque | HEK293 | ![]() | MALSSDS-PAGE | $395.00 100ug | |
| CD27 | HOT CD7-H5254 | Human CD27 / TNFRSF7 Protein, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $310.00 200ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Varlilumab | CDX-1127 | Phase 2 Clinical | Celldex Therapeutics | Adenocarcinoma; Astrocytoma; Bile Duct Neoplasms; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Lymphoma; Cholangiocarcinoma; Gallbladder Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hormone-Resistant Prostate Neoplasms; Kidney Diseases; Kidney Neoplasms; Large intestine neoplasm; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Primary Effusion; Lymphoma, T-Cell; Lymphomatoid Granulomatosis; Melanoma; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Plasmablastic Lymphoma; Prostatic Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urologic Diseases; Urologic Neoplasms | Details |
| Boserolimab | MK-5890 | Phase 1 Clinical | BioNovion Holding BV | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Solid tumours; Triple Negative Breast Neoplasms | Details |
| LOR-S03 | CDX-527 | Phase 1 Clinical | Celldex Therapeutics | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Anti-CD27 monoclonal antibody (Aduro Biotech) | BION-1402 | Phase 1 Clinical | Aduro Biotech Inc | Neoplasms | Details |